| Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo R Das, R Verma, M Sznol, CS Boddupalli, SN Gettinger, H Kluger, ... The Journal of Immunology 194 (3), 950-959, 2015 | 258 | 2015 |
| Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation S Nair, CS Boddupalli, R Verma, J Liu, R Yang, GM Pastores, PK Mistry, ... Blood 125 (8), 1256-1271, 2015 | 88 | 2015 |
| Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. DMV Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru ... Blood 125 (26), 4042-51, 2015 | 70* | 2015 |
| Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells CS Boddupalli, N Bar, K Kadaveru, M Krauthammer, N Pornputtapong, ... JCI insight 1 (21), 2016 | 65 | 2016 |
| Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice R Verma Nature Medicine. 2016 November ; 22(11): 1351–1357 (https://www.ncbi.nlm.nih …, 2016 | 60* | 2016 |
| Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice R Verma Nature Medicine 22, 22, 1351–1357 (2016), 2016 | 60* | 2016 |
| Significantly reduced regulatory T cell population in patients with untreated multiple myeloma R Gupta, P Ganeshan, M Hakim, R Verma, A Sharma, L Kumar Leukemia research 35 (7), 874-878, 2011 | 54 | 2011 |
| ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells CS Boddupalli, S Nair, SM Gray, HN Nowyhed, R Verma, JA Gibson, ... The Journal of clinical investigation 126 (10), 3905-3916, 2016 | 40 | 2016 |
| Complete response after autologous stem cell transplant in multiple myeloma L Kumar, N Iqbal, A Mookerjee, RK Verma, OD Sharma, A Batra, ... Cancer medicine 3 (4), 939-946, 2014 | 24 | 2014 |
| Erythropoietin-directed erythropoiesis depends on serpin inhibition of erythroblast lysosomal cathepsins A Dev, SM Byrne, R Verma, PG Ashton-Rickardt, DM Wojchowski Journal of Experimental Medicine 210 (2), 225-232, 2013 | 21 | 2013 |
| Recent advances in the management of multiple myeloma L Kumar, R Verma, VR Radhakrishnan The National medical journal of India 23 (4), 210-218, 2010 | 19 | 2010 |
| Defining an EPOR-regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO-dependent erythroblast formation S Singh, A Dev, R Verma, A Pradeep, P Sathyanarayana, JM Green, ... PloS one 7 (7), e38530, 2012 | 18 | 2012 |
| RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast development R Verma, S Su, DJ McCrann, JM Green, K Leu, PR Young, PJ Schatz, ... Journal of Experimental Medicine 211 (9), 1715-1722, 2014 | 17 | 2014 |
| Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles S Singh, R Verma, A Pradeep, K Leu, RB Mortensen, PR Young, M Oyasu, ... PloS one 7 (1), e29064, 2012 | 14 | 2012 |
| Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial AR Branagan, E Duffy, RA Albrecht, DL Cooper, S Seropian, TL Parker, ... Clinical Lymphoma Myeloma and Leukemia 17 (5), 296-304. e2, 2017 | 13 | 2017 |
| Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial A Naing, DJ Wong, JR Infante, WM Korn, R Aljumaily, KP Papadopoulos, ... The Lancet Oncology, 2019 | 8 | 2019 |
| Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs R Verma, Z Mai, M Xu, L Zhang, K Dhodapkar, MV Dhodapkar Blood 126 (23), 913-913, 2015 | 5 | 2015 |
| Two dose series of high-dose influenza vaccine is associated with longer duration of serologic immunity in patients with plasma cell disorders A Branagan, E Duffy, C Foster, R Verma, L Zhang, G Gan, F Li, ... Blood 130 (Suppl 1), 438-438, 2017 | 4 | 2017 |
| A dimeric peptide with erythropoiesis-stimulating activity uniquely affects erythropoietin receptor ligation and cell surface expression R Verma, JM Green, PJ Schatz, DM Wojchowski Experimental hematology 44 (8), 765-769. e1, 2016 | 4 | 2016 |
| Comparison of intermittent and continuous dosing regimens of pomalidomide in relapsed/refractory myeloma: results of a phase II randomized trial K Sehgal, MH Kocoglu, Y Deng, R Verma, L Zhang, DL Cooper, X Yao, ... Blood 122 (21), 3205-3205, 2013 | 3 | 2013 |
Richard A. FlavellSterling Professor of Immunobiology, Yale University, HHMI InvestigatorVerified email at yale.edu
